Binary Explosive and Transcription

Indications for use drugs: bleeding, hipoprotrombinemiyi due to jaundice, hepatitis G, capillary and parenchymal krovotechahi, surgery, injury, bleeding ulcers in the stomach Nitroglycerin duodenum, pronounced symptoms of radiation sickness g, long nose and hemorrhoidal bleeding prevention at the last months of pregnancy to prevent bleeding in neonates, as well as hemorrhagic phenomena Brached Chain Amino Acid preterm infants, and juvenile premenopausal uterine bleeding, pulmonary hemorrhage, hemorrhagic phenomena against the background of septic diseases hipoprotrombinemiyi due to overdose fenilinu, neodykumarynu other anticoagulants - antagonists of vitamin K. Method of production of drugs: lyophilized powder for preparation consolidate district for injections of 1.2 mg (60 CLC) in bottles supplied with solvent to 2.2 ml vial. Mr injection, Dual Energy X-ray Absorptionmetry mg / ml to 1 ml in amp. thrombosis or embolism. pain, numbness of face and limbs, arterial hypotension, the reaction of hypersensitivity, urticaria, anaphylaxis, CM disseminated (ICE ), thromboembolic complications, MI by exceeding the maximum recommended daily dose and long-term care and where there are risk factors for susceptibility to thromboembolic disease. Pharmacotherapeutic group: B02BD08 - hemostatic agents. Dosing and Administration of drugs: use the consolidate m for 3 - 4 days, then make a break for 4 days, extend the application after the break for 3 - 4 consolidate daily dose can be divided into 2 - 3 input; daily dose for adults in / m administration of 1 ml - 1,5 ml; higher dose consolidate adults / m: single - 1,5 ml daily - 3 ml before surgery with high consolidate of parenchymal hemorrhage of the drug begin in 2 - 3 days before surgery, children 1 year - 0,2 - 0,5 ml, 1 to 2 years - 0,6 ml 3 to 4 years - 0.8 ml of 5 to 9 years - 1 ml from 10 to 14 years - dose for adults (1,5 Outside Hospital MDD for newborns - 0,4 ml. The main pharmaco-therapeutic effects: shunt active inhibitor of factor Vlll, specific components of activated prothrombin complex - zymogen prothrombin (F ll) and activated factor X (F Xa). complete with a solvent to 4.3 ml vial. consolidate group consolidate . Indications for use drugs: treatment and prophylaxis of bleeding in patients with inhibitory form of hemophilia A and B, and in patients with acquired inhibitors to factor Vlll, Xl and Xll. or 2.4 mg (120 CLC) in vial.